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Tuberculosis transmission oustide the home
R. Wood
Desmond Tutu HIV Foundation, Cape Town, South
Africa
The history of tuberculosis has been viewed from the indus-
trialised world perspective. TB incidence peaked in the mid-19th
century and steadily decreased over the subsequent century. The
current world distribution of TB shows that incidence is greatest in
non-industrialised countries of sub-Saharan Africa and Asia. South
Africa and Swaziland currently have the highest TB burdens in the
world where more than 1% of their populations develop TB each
year. Cape Town is one of themost heavily TB burdened cities in the
world with more TB disease notiﬁed annually than the combined
numbers of USA, Canada and UK. A comparison of South African
and New York TB before chemotherapy demonstrates a 5- to 10-
fold decline in TB in New York due to social and environmental
factors, which did not occur in Cape Town. In addition to very high
TB rates among people living with HIV, HIV-negative individuals
living in Cape Town have similar TB burdens as reported a cen-
tury ago. We therefore went on to explore and quantify the social
and environmental locations and environmental factors maintain-
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The interaction between antimicrobial and
adjunctive therapies and the immune response
to tuberculosis
R. Wilkinson
University of Cape Town, Cape Town, South Africa
HIV-1 infected patients co-infected with some pathogens are
at risk of developing of the immune reconstitution inﬂammatory
syndrome (IRIS) when initiating antiretroviral therapy (ART). IRIS
is characterized by inﬂammation leading to the clinical worsening
of a treated infection or the unmasking of a previously undiagnosed
condition or infection. It is commonly associated with tuberculosis
(TB), 8-43% of the HIV-TB co-infected patients prescribed antitu-
bercular treatment and ART develop TB-IRIS. Although IRIS has
been recognised for over 20 years, relatively little was known until
recently about its pathogenesis. Despite these advances in under-
standing IRIS, there remains no immune biomarker for diagnostic
or prognostic purposes. This talk will review the risk factors asso-
ciated with TB-IRIS, the challenges in studying this syndrome, and
how T lymphocytes, dysregulated cytokine responses and innate
immunity may contribute to the development of TB-IRIS.
http://dx.doi.org/10.1016/j.ijid.2014.03.575
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The role of vitamin D in tuberculosis
pathogenesis and treatment
A. Martineau
Queen Mary University of London, London, United
Kingdom
Tuberculosis (TB) is amajor causeofmortality, responsible foran
estimated 1.4 million deaths worldwide in 2011. The global preva-
lence of latent Mycobacterium tuberculosis infection is estimated to
be 32%, and this carries a 5–20% lifetime risk of reactivation disease.
The emergence of drug-resistant organisms necessitates the devel-
opment of new agents to enhance the response to antimicrobial
therapy for active TB. Vitamin D was used to treat TB in the pre-
antibiotic era, and its active metabolite, 1,25-dihydoxyvitamin D,
has longbeenknown toenhance the immune response tomycobac-
teria in vitro. Vitamin D deﬁciency is common in patients with
active TB, and several clinical trials have evaluated the role of
adjunctive vitamin D supplementation in its treatment. Results of
these studies are conﬂicting, reﬂecting variationbetween studies in
baseline vitaminD status of participants anddosing regimens. Vita-
min D deﬁciency is also recognised to be highly prevalent among
people with latent M. tuberculosis infection in both high- and low-
burden settings, and observational epidemiological evidence links
vitamin D deﬁciency with increased risk of both acquisition and
reactivation of latent M. tuberculosis infection. Randomised con-
trolled trials of vitamin D supplementation for the prevention of
latent infection or active disease have yet to be performed, how-
ever. The conduct of such trials is a research priority, given the
safety and low cost of vitamin D supplementation, and the signiﬁ-
cant public health consequences of positive results.
http://dx.doi.org/10.1016/j.ijid.2014.03.576
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New drugs for the treatment of tuberculosis
A. Diacon
Stellenbosch, South Africa
Prior to the introduction of chemotherapy tuberculosismanage-
ment relied upon aerotherapy, heliotherapy and good nutrition.
Tuberculosis chemotherapy began in 1944 with the introduction
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of streptomycin and para-amino-salicylic acid, later augmented
by isoniazid. Between 1970-1980 rifampicin was introduced and
with isoniazid and pyrazinamide made “short-course” 6-months
treatment possible. The recent epidemic spread of HIV/AIDS and
an increase in antituberculosis drug-resistance, making tuberculo-
sis virtually untreatable in some instances, has placed tuberculosis
programmes under severe pressure. New treatment regimens are
direly needed.
For theﬁrst time indecades, therearenowmultiplenewdrugs in
the pipeline for the treatment of tuberculosis. In addition, existing
drugs are being repurposed or optimized with the goal of short-
ened treatment duration for drug-sensitive tuberculosis and safer,
shorter treatments for multidrug-resistant tuberculosis. High-
dose rifamycins and ﬂuoroquinolones have treatment-shortening
potential when used for drug-sensitive tuberculosis. Bedaquiline,
an antituberculosis drug with a novel mechanism of action, and
delamanid, a nitroimidazole, are entering phase 3 trials. Both
improve rates of sputum culture conversion among patients with
drug resistant tuberculosis. Other nitroimidazoles and oxazolidi-
nones are in Phase 2 testing, as are combinations involvingmultiple
new chemical entities.
Development of novel antituberculosis agents and regimens
currently involves determination of early bactericial activity over
the ﬁrst 14 days of treatment as the ﬁrst clinical investigation
undertaken to establish a basic relationship betweendose and anti-
tuberculosis activity and obtain limited information about safety
and tolerability. The information obtained is reﬁned in Phase 2
studies over 8-weeks that prepare the ground for deﬁnite Phase
3 studies for the conduct of which considerable capacity building
and funding is still required.
A biomarker for early indication of treatment effects or cure
couldgreatly simplify antituberculosis regimendevelopment. Clear
identiﬁcation of the different populations of mycobacteria that are
present in sputum at the start of treatment, and measurement of
their rise or fall, could contribute to the identiﬁcation of early sig-
nals of drug activity that provide sterilization of lesions. This area
will start to be resolved only when the results of long-term stud-
ies of new regimens regarding relapse rates become available and
candidate biomarkers can be validated.
http://dx.doi.org/10.1016/j.ijid.2014.03.577
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Antimicrobial stewardship: Limits for
implementation
B. Sinha
University Medical Center Groningen, Groningen,
Netherlands
Antibiotic stewardship programme (ASP) is a multifaceted
approach to improve patients’ clinical outcomes, prevent the emer-
gence of antimicrobial resistance, and reduce hospital costs by
prudent and focused antimicrobial use. Development of local treat-
ment guidelines according to local ecology, rapid diagnostic in
microbiology laboratory, dosage optimization following pharma-
cokinetic and pharmacodynamic proﬁles, formulary restriction for
speciﬁc classes of antibiotics, appropriate duration of antibiotic
treatment, ICU and wards speciﬁc antibiograms, programs of con-
tinuous education, feedback and prospective audit for healthcare
workers, are fundamental components of an efﬁcient ASP. Numer-
ous studies have showed that it is possible to change antibiotic
prescription attitudes in hospital, at different ecological, cultural
and economical levels and ASP might play a signiﬁcant role in
the reduction of colonization and infections caused by antibiotic-
resistant bacteria. Major risk in implementing ASP is the lack of
consideration of local ecology and strict quality indicators. There
is still an open debate over which outcomes to measure and the
appropriate studydesign that canobjectively assessASPdespite the
limitations inherent in the structure of most such programs. Euro-
pean networks to deﬁne best strategies and antibiotic-care bundles
need to be supported at national and international level.
http://dx.doi.org/10.1016/j.ijid.2014.03.578
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Social media for stewardship: Progress or a
waste of time?
D. Goff
Ohio State University Wexner Medical Centre,
Columbus, USA
Do you think the word “tweet” means the sound a bird makes?
If a patient says “Doctor help me I’m addicted to twitter! and
the doctor replies, “Sorry I don’t follow you”, are you laughing?
If not, then this lecture will help you learn how to apply social
media (Twitter and Facebook) in a meaningful way for antimicro-
bial stewardship programs (ASP). Health care providers who are
expert Twitter-users state that Twitter is worth taking the time
to ﬁgure out because of its powerful ability to amplify a message
above and beyond current audiences. The world is losing the battle
against antimicrobial resistant organisms. Antimicrobial stewards
needs to engage colleagues, patients and consumers to under-
stand that antibiotic resistance is one of the world’s most pressing
public health threats. Peer-reviewed articles in ID journals do not
reach these audiences therefore additional strategies are neces-
sary. Twitter for stewardship has a 2-fold purpose. First it can help
advocate the stewardship message to preserve antibiotics. Sec-
ondly, twitter allows one to discover, interact and learn from other
infectious diseases stewardship expert’s worldwide. The twitter
user must ﬁnd a niche (stewardship) and then start to engage in
trending topics (#antibioticresistance). The user can be passive on
twitter and choose to follow organizations (@IDSAInfo @ECCMID
@SouthAfricanASP @CDC eHealth @WHO) or speciﬁc stewardship
healthcare advocates (@IDPharmD) or the user can be become
active and send out “tweets” that help advocate ASP. This is espe-
cially helpful for resource limited countries because twitter is free
to use. Globally, there are over 1.1 billion people on Facebook. It
allows the user to discover and interact with interesting people or
organizations in the ﬁeld of antimicrobial stewardship. This lec-
ture will demonstrate how the CDC used Facebook to identify an
outbreak in real-time and then connect with individuals to resolve
the outbreak. The power behind socialmedia and its impact on get-
ting theantimicrobial stewardshipmessageout to theworld should
